

1 **Higher ratio of plasma omega-6/omega-3 fatty acids is associated**
2 **with greater risk of all-cause, cancer, and cardiovascular mortality:**
3 **a population-based cohort study in UK Biobank**

4

5

6 **Authors:** Yuchen Zhang, MPH¹; Yitang Sun, MPH²; J. Thomas Brenna, PhD^{3,4}; Ye Shen,
7 PhD^{1*}; Kaixiong Ye, PhD^{2,5*}

8

9 **Author Affiliations:**

10 ¹ Department of Epidemiology and Biostatistics, College of Public Health, University of Georgia,
11 Athens, Georgia, US

12 ² Department of Genetics, University of Georgia, Athens, Georgia, US

13 ³ Division of Nutritional Sciences, Cornell University, Ithaca, NY, US

14 ⁴ Dell Pediatric Research Institute and the Depts of Pediatrics, of Nutrition, and of Chemistry,
15 University of Texas at Austin, Austin, TX, US

16 ⁵ Institute of Bioinformatics, University of Georgia, Athens, Georgia, US

17 * YS and KY jointly supervised this project.

18

19 **Corresponding Author:**

20 Kaixiong Ye, PhD

21 Department of Genetics, C220 Davison Life Sciences Complex, University of Georgia, 120 East
22 Green Street, Athens, GA 30602

23 Phone: 706-542-5898 Email: kaixiong.ye@uga.edu

24

25

26

27

28 **Abstract**

29 **Background**

30 Circulating omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) have been associated
31 with various chronic diseases and mortality, but results are conflicting. Few studies examined the
32 role of a balanced omega-6/omega-3 ratio in mortality.

33 34 **Methods**

35 We investigated plasma omega-3 and omega-6 PUFAs and their ratio in relation to all-cause and
36 cause-specific mortality in a large prospective cohort, the UK Biobank. Of 117,546 participants
37 who had complete information on circulating PUFAs, 4,733 died during follow-up, including
38 2,585 from cancer and 1,017 from cardiovascular disease (CVD). Associations were estimated
39 by multivariable Cox proportional hazards regression with adjustment for relevant risk factors.

40 41 **Results**

42 Results: Risk for all three mortality outcomes increased as the ratio of omega-6/omega-3 PUFAs
43 increased (all $P_{\text{trend}} < 0.001$). Comparing the highest to the lowest quintiles, individuals had 42%
44 (95% CI, 28-57%) higher total mortality, 31% (95% CI, 13-50%) higher cancer mortality, and 40%
45 (95% CI, 12-75%) higher CVD mortality. Moreover, omega-3 and omega-6 PUFAs in plasma
46 were all inversely associated with all-cause, cancer, and CVD mortality, with omega-3 showing
47 stronger effects.

48 49 **Conclusions**

50 Using a population-based cohort in UK Biobank, our study revealed a strong association between
51 the ratio of circulating omega-6/omega-3 PUFAs and the risk of all-cause, cancer, and CVD
52 mortality.

53 54 **Keywords**

55 Polyunsaturated fatty acids, Omega-3 fatty acids, Omega-6 fatty acids, Mortality, Prospective
56 studies

57

58 **Background**

59
60 Cancer and cardiovascular disease (CVD) are the two leading causes of non-communicable
61 disease mortality globally¹. Substantial epidemiologic evidence has linked the dietary or
62 circulating levels of omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) to the risks of
63 all-cause, cancer, and CVD mortality (**Additional file 1: Table S1**). However, the results are
64 inconsistent, especially for omega-6 PUFAs. Most large observational studies support the
65 protective effects of omega-3 PUFAs. In addition to total and individual omega-3 PUFAs, the
66 omega-3 index, defined as the percentage of eicosapentaenoic acid (EPA) and docosahexaenoic
67 acid (DHA) in total fatty acids in red blood cells, was shown to be a validated biomarker of the
68 dietary intake and tissue levels of long-chain omega-3 PUFAs, and was proposed to be a risk
69 factor for CVD and related mortality^{2,3}. While the omega-3 index has been observed to be
70 inversely associated with all cause-mortality, its association patterns with CVD and cancer
71 mortality are less clear⁴⁻⁶. Most importantly, results from clinical trials of omega-3 PUFA
72 supplementation have been inconsistent^{7,8}. On the other hand, while some studies revealed
73 inverse associations of omega-6 PUFAs with all-cause mortality⁹⁻¹¹, others reported null
74 results^{4,12-15}. The role of omega-6 PUFAs in cancer and CVD mortality is less studied, and the
75 patterns are similarly conflicting^{4,9-11}. Interpreting previous observational results is challenging
76 due to the limitations of small sample sizes, insufficient adjustments for confounding, and unique
77 sample characteristics. Moreover, many studies rely on self-reported dietary intake or fish oil
78 supplementation status, which are subject to large variability and reporting bias¹⁶. Despite the
79 tremendous interest and research effort, the roles of omega-3 and omega-6 PUFAs in all-cause
80 and cause-specific mortality remain controversial.

81

82 It has been suggested that the high omega-6/omega-3 ratio in Western diets, 20:1 or even higher,
83 as compared to an estimated 1:1 during the most time of human evolution, contributes to many
84 chronic diseases, including CVD, cancer, and autoimmune disorders^{17,18}. However, while many
85 previous studies have examined total or individual omega-3 and omega-6 PUFAs, fewer
86 investigated the role of their imbalance, as measured by the omega-6/omega-3 ratio, in
87 mortality^{4,14,15,19}. In a prospective cohort study of postmenopausal women, the omega-6/omega-3
88 ratio in red blood cells was associated with an increased risk of all-cause mortality but not with
89 cancer or CVD mortality⁴. Similar positive associations with all-cause mortality were observed
90 in smaller cohorts investigating the ratio in serum or dietary intake^{14,19}. However, prospective
91 studies in two independent cohorts from China and US did not find a linear positive association
92 between the omega-6/omega-3 ratio in diet and all-cause mortality¹⁵. To address these gaps in
93 our understanding of the roles of omega-3 and omega-6 PUFAs and their imbalance in all-cause
94 and cause-specific mortality, we perform a prospective study in a large population-based cohort
95 (N = 117,546) from UK Biobank, using objective measurements of PUFA levels in plasma.

96

97 **Methods**

98 *Study population*

99 The UK Biobank study is a prospective, population-based cohort study in the United Kingdom²⁰.
100 Between 2006 and 2010, 502,536 prospective participants, aged 40-69, in 22 assessment Centers
101 throughout the UK were recruited for the study. The population information was collected
102 through a self-completed touch-screen questionnaire; brief computer-assistant interview;
103 physical and functional measures; and blood, urine, and saliva collection during the assessment
104 visit. Participants with incomplete data on the plasma omega-6/omega-3 ratio (n=383,692) and

105 those who withdrew from the study (n=1,298) were excluded from this study, leaving 117,546
106 participants, 4,733 died during follow-up, including 2,585 from cancer and 1,017 from CVD.

107

108 *Ascertainment of exposure*

109 Omega-3 and omega-6 PUFAs were measured by nuclear magnetic resonance (NMR) in plasma
110 samples collected between 2007 and 2010²⁰⁻²².

111

112 *Ascertainment of outcome*

113 The date and cause of death were identified through the death registries of the National Health
114 Service (NHS) Information Centre for participants from England and Wales and the NHS Centre
115 Register Scotland for participants from Scotland²⁰. At the time of the analysis (3 May 2022),
116 mortality data were available up to 14 February 2018 for England and Wales and 31 December
117 2016 for Scotland. Therefore, follow-up time was calculated as the time between the date of
118 entering the assessment Centre and this date, or the date of death, whichever happened first. The
119 underlying cause of death was assigned and coded in vital registries according to the ICD-10
120 (International Classification of Diseases, 10th revision). CVD mortality was defined using codes
121 I00-I99, and cancer mortality was defined using codes C00-D48.

122

123 *Ascertainment of covariates*

124 The baseline questionnaire included detailed information on several possible confounding
125 variables: demographic factors (age, sex, assessment Centre, ethnicity), socioeconomic status
126 (Townsend Deprivation Index), lifestyle habits (alcohol assumption, smoking status, body mass
127 index (BMI), physical activity) and other supplementation (Fish-oil supplementation).

128

129 *Statistical analysis*

130 We summarized and compared the characteristics of the participants across quintiles of the
131 omega-6/omega-3 ratio at baseline using descriptive statistics. Pearson's Chi-squared test and
132 ANOVA test were used to compare the demographic characteristics across quintiles, respectively,
133 for categorical variables and continuous variables. To investigate associations of the ratio with
134 cause-specific and all-cause mortality, we used multivariable Cox proportional hazards
135 regression models to calculate hazard ratios²³ and their 95% confidence intervals (CI). The
136 proportional hazards assumption was not violated based on Schoenfeld residuals. We analyzed
137 the ratio as continuous and categorical variables (i.e., quintiles). For all trend tests, we used the
138 median value of each quintile as a continuous variable in the models. Potential nonlinear
139 associations were assessed semi-parametrically using restricted cubic splines (4 knots were used
140 in regression splines)²⁴.

141

142 Based on previous literature and biological plausibility^{11,25,26}, we chose the following variables
143 as covariates in the multivariate models: age (years; continuous), sex (male, female), race (White,
144 Black, Asian, Others), Townsend deprivation index (continuous), assessment Centre, BMI
145 (kg/m²; continuous), smoking status (never, previous, current), alcohol intake status (never,
146 previous, current), physical activity (low, moderate, high).

147

148 In secondary analyses to assess potential differences in associations across different population
149 subgroups, we repeated the above-described analyses stratified by age (< vs. ≥ the median age of
150 58 years), sex (male/female), Townsend deprivation index (< vs. ≥ the population median of -2),

151 BMI ($< vs. \geq 25$), current smoking status (yes vs. no), and physical activity (low and moderate
152 vs. high).

153

154 We also conducted several sensitivity analyses. First, to assess whether the associations of the
155 omega-6/omega-3 ratio with mortality outcomes were primarily driven by omega-3 fatty acids or
156 omega-6 fatty acids, we assessed both the separate and the joint associations of omega-3 fatty
157 acids to total fatty acids percentage (omega-3%) and omega-6 fatty acids to total fatty acids
158 percentage (omega-6%) with the three mortality outcomes. We also performed a joint analysis
159 with categories of the omega-3% and omega-6% quintiles, using participants in both the lowest
160 omega-3% and omega-6% quintiles as the reference category. An interaction term between
161 omega-3% and omega-6% was included in the multivariable Cox proportional hazards model,
162 and a Wald test was used to assess its significance. The correlation between omega-3% and
163 omega-6% was assessed by the Spearman correlation. Second, to address the potential residual
164 confounding by fish oil supplementation, we further adjusted for the supplementation status from
165 the baseline questionnaire. Third, to investigate the effects of missing values, we imputed
166 missing values ($<1\%$ for most factors, up to 19% for physical activity) by chained equations and
167 performed synthesis analyses on the imputed datasets²⁷. Fourth, to assess whether the observed
168 associations are attenuated by reverse causation, we excluded those who died in the first year of
169 follow-up. Last, to assess the representativeness of the participants included in our study, we
170 compared the baseline characteristics between the participants with and without exposure
171 information. All P-values were two-sided. We considered a P-value ≤ 0.05 or a 95% confidence
172 interval (CI) excluding 1.0 for HRs as statistically significant. We conducted all analyses using R,
173 version 4.0.3.

174

175 **Results**

176 *Baseline characteristics*

177 In the analytic cohort of 117,546 participants, over a mean of 8.9 years of follow-up, 4,733 died,
178 including 2,585 from cancer and 1,017 from CVD. The baseline characteristics of the
179 participants across quintiles of the ratio of omega-6/omega-3 were summarized in **Table 1**. Study
180 participants were, on average, 57 years old and 91% White. Those in the higher ratio quintiles
181 were more likely to be younger, male, and current smokers, but less likely to take fish oil
182 supplementation.

183

184 *Main results*

185 The associations of the omega-6/omega-3 ratio with all-cause and cause-specific mortality risks
186 were presented in **Table 2**. A higher ratio was strongly associated with higher mortality from all
187 causes, cancer, and CVD ($P_{\text{trend}} < 0.001$ for all three). In the fully adjusted models that
188 considered the ratio as a continuous variable, every unit increase in the ratio corresponded to 2%,
189 1%, and 2% higher risk in all-cause, cancer, and CVD mortality, respectively. When
190 comparisons were made between the highest and the lowest quintile of the omega-6/omega-3
191 ratio, there were 42%, 31%, and 40% increased risk for all-cause, cancer, and CVD mortality,
192 respectively.

193

194 *Stratified analysis*

195 The fully adjusted associations of the omega-6/omega-3 ratio with all-cause mortality revealed
196 that compared to the lowest quintile, the highest quintile has strong, statistically significant

197 associations with elevated risk within all categories of sex, TDI, BMI, smoking status, and
198 physical activity (**Figure 1, Additional file 2: Table S2**), except in those aged less than 58 years
199 old. The estimated associations with all-cause mortality were stronger in current smokers and
200 those with a higher TDI (P for interaction < 0.01 and = 0.02, respectively; **Figure 1**). For cancer
201 and CVD mortality, they also tended to be stronger among current smokers (P for interaction =
202 0.01 and 0.05, respectively). No significant interactions were found for other risk factors (**Figure**
203 **2**).

204

205 *Restricted cubic spline analysis*

206 Restricted cubic spline analysis suggested significant positive associations of the omega-
207 6/omega-3 ratio with all-cause, cancer, and CVD mortality (P < 0.01 for all three outcomes,
208 **Figure 3**). Potential nonlinearity in these positive associations was identified for all-cause
209 mortality (P = 0.011) and CVD mortality (P = 0.011) but not for cancer mortality (P > 0.05). The
210 strength of the relationship between the ratio and all-cause mortality appears to remain at a
211 relatively low level before it starts to increase quickly after the ratio exceeds 8. A similar trend
212 with higher uncertainties was observed for CVD mortality.

213

214 *Omega-3, Omega-6, and Joint analysis*

215 We further performed analyses to assess whether the associations of the omega-6/omega-3 ratio
216 with mortality outcomes were primarily driven by omega-3 or omega-6 fatty acids. The
217 correlation between the omega-3% and omega-6% was relatively low with $r = 0.12$ (P < 0.01).
218 Across all models, both the omega-3% and omega-6% were inversely associated with all three
219 mortality outcomes (P_{trend} < 0.001 for both exposures and all three outcomes, **Additional file 2:**

220 **Table S3 and Table S4**). Notably, their associations remained significant when they were
221 included in the same models. On the other hand, the effect sizes of the inverse associations were
222 always bigger for the omega-3%. For example, when comparing those in the highest omega-3%
223 quintile to the lowest quintile, the fully adjusted HRs (95% CI) for all-cause, cancer, and CVD
224 mortality were, respectively, 0.62 (0.55, 0.68), 0.68 (0.59, 0.79), and 0.62 (0.49, 0.78)
225 (**Additional file 2: Table S3**). The corresponding HRs for the omega-6% were 0.81 (0.72, 0.90),
226 0.78 (0.67, 0.91), and 0.87 (0.67, 1.12) (**Additional file 2: Table S4**). Furthermore, in another
227 joint analysis of the omega-3% and omega-6%, the lowest risk for all three mortality outcomes
228 was observed among those in the joint highest categories of the two fatty acids (**Additional file 2:**
229 **Table S5**). For example, when comparing those in the highest quintiles of the two fatty acids to
230 the group with the joint lowest group, the HRs (95% CI) for all-cause, cancer, and CVD
231 mortality were, respectively, 0.46 (95% CI, 0.32, 0.66), 0.41 (95% CI, 0.25, 0.68), and 0.77 (95%
232 CI, 0.36, 1.64).

233

234 *Other sensitivity analyses*

235 After further adjustment of the fish oil supplementation status, the associations between the ratio
236 of omega-6/omega-3 and mortality outcomes were slightly attenuated yet did not alter the main
237 findings (**Additional file 2: Table S6**). Our primary analysis excluded participants with missing
238 information (i.e., a complete-case analysis). We performed a sensitivity analysis using the
239 multiply-imputed datasets, and there were no substantial changes (**Additional file 2: Table S7**).
240 Moreover, the exclusion of participants who died during their first-year follow-up did not
241 materially alter the results (**Additional file 2: Table S8**). The baseline characteristics are

242 comparable between participants with or without exposure information (**Additional file 2: Table**
243 **S9**).

244
245 **Discussion**

246 In this prospective population-based study of UK individuals, we showed that a higher ratio of
247 plasma omega-6/omega-3 fatty acids was positively associated with the risk of all-cause, cancer,
248 and CVD mortality. These associations were independent of most risk factors examined,
249 including age, sex, BMI, and physical activity, but they were all stronger in current smokers.
250 These relationships were linear for cancer mortality but not for all-cause and CVD mortality. For
251 those two outcomes, the risk of mortality first decreased at lower ratios and then increased, with
252 an inflection point around the ratio of 8. Moreover, omega-3 and omega-6 PUFAs in plasma
253 were consistently and inversely associated with all-cause, cancer, and CVD mortality, with
254 omega-3 showing stronger effects.

255
256 To date, studies that examined the relationship between the ratio of omega-6/omega-3 PUFAs
257 and mortality in the general population are sparse^{4,14,15,19}. Similar to our finding, in a 2017 report
258 from a prospective women cohort study (n=6,501; 1,875 all-cause deaths, 617 CVD deaths, 462
259 cancer deaths)⁴, the adjusted HR for all-cause mortality was 1.10 (1.02-1.19) per 1-SD increase
260 of omega-6/omega-3 ratio in red blood cells, however, the effects were not significant for cancer
261 and CVD deaths. Another study supporting our results was conducted on elderly Japanese
262 individuals (n=1,054; 422 deaths). It found that the ratio of an omega-3 fatty acid,
263 eicosapentaenoic acid, to an omega-6 fatty acid, arachidonic acid (ARA), is inversely associated
264 with all-cause mortality, with an HR of 0.71 (95% 0.53–0.96) comparing the highest to the
265 lowest tertile¹⁴. Findings of previous studies based on dietary intake were null^{15,19}. A prospective

266 cohort involving 145 hemodialysis patients enrolled in Southern California during 2001-2007
267 (42 all-cause deaths) showed that the estimated HR (95% CI) for all-cause mortality among those
268 in the lowest relative to the highest quartiles of dietary omega-6/omega-3 ratio was 0.37 (0.14-
269 1.08)¹⁹. Although the effect was not significant, it still shows the protective trend of a lower
270 omega-6/omega-3 ratio against premature death, when taking the sample size and study
271 population into consideration. In a 2019 report based on two population-based prospective
272 cohorts in China (n=14,117, 1,007 all-cause deaths) and the US (n=36,032, 4,826 all-cause
273 deaths), the effect of the omega-6/omega-3 ratio intake was not significant (HR (95% CI) is 0.95
274 (0.80-1.14) for China and 0.99 (0.89-1.11) for US, respectively)¹⁵. These discrepancies may be
275 explained by the usage of circulating biomarkers or dietary intakes for calculating the omega-
276 6/omega-3 ratio. The estimated dietary intakes may be inaccurate due to recall bias or outdated
277 food databases¹⁶. The circulating level is a more objective measurement of PUFA status and thus
278 provides a more reliable picture of the effects of omega-3 and omega-6 PUFAs on mortality.

279
280 A large number of existing observational studies documented the reverse association of
281 circulating levels and intake of omega-3 PUFAs with mortality^{5,6,26,28-33}, which is in line with our
282 finding that individuals in the highest quintile of the omega-6/omega-3 ratio had approximately
283 40% higher risk for all-cause and CVD mortality and 30% higher risk for cancer mortality, when
284 compared to those in the lowest quintile. Few previous studies have examined the association in
285 generally healthy populations^{6,26,28,30}. In a 2016 meta-analysis³⁰ of seven epidemiologic studies
286 for dietary omega-3 PUFAs intake and four studies for circulating levels, the estimated relative
287 risk for all-cause mortality was 0.91 (95% CI: 0.84-0.98) when comparing the highest to the
288 lowest categories of omega-3 PUFA intake. In two 2018 reports of population-based studies in

289 the US, the circulating level and dietary intake of omega-3 PUFAs were significantly associated
290 with lower total mortality^{6,26}. In a 2021 meta-analysis of 17 epidemiologic studies, comparing
291 the highest to the lowest quintiles of circulating EPA and DHA, the estimated HRs for all-cause,
292 CVD, and cancer mortality were 0.84 (0.79-0.89), 0.80 (0.73-0.88) and 0.87 (0.78-0.96),
293 respectively²⁸. Moreover, inverse associations of omega-3 PUFAs biomarkers with total
294 mortality were found in patients with myocardial infarction^{31,32}, type 2 diabetes¹², and other
295 diseases^{5,29,33,34}; inverse associations of omega-3 PUFAs with CVD mortality were also reported
296 in these patient groups^{5,12,31}. However, there are also reports of a null relationship between
297 omega-3 PUFAs and mortality^{13,14,35}. One possible explanation for the discrepancies could be the
298 limited statistical power due to the small sample size and the small number of events. Moreover,
299 the inconsistency may be due to unique sample characteristics; one study only involved elder
300 patients¹⁴, and one only involved women³⁵.

301
302 A smaller number of studies have evaluated the associations of omega-6 PUFAs with mortality.
303 Our findings in the large UK prospective cohort are in accordance with the results of several
304 previous studies that increased circulating levels of omega-6 PUFAs were associated with
305 decreased all-cause mortality^{9,11,15,36}. Moreover, a 2019 meta-analysis involving 18 cohort
306 studies and 12 case-control studies showed that an omega-6 PUFA, linoleic acid, was inversely
307 associated with CVD mortality; the HR per interquintile range was 0.78 (95% CI, 0.70-0.85)¹⁰.
308 Other studies, however, did not support such reverse associations^{4,12-14,35}. Although the findings
309 were inconsistent, no previous studies reported harmful effects of omega-6 PUFAs on
310 mortality^{4,11-15,35-38}. Our studies support the protective effects of omega-6 PUFAs on all-cause

311 and cause-specific mortality. Further research is needed to investigate the health impacts of
312 omega-6 PUFAs in laboratory studies, epidemiological investigations, and clinical trials.

313
314 Strengths of our current study include the use of objective PUFA biomarkers in plasma instead
315 of the estimated intakes from dietary questionnaires, which increases the accuracy of exposure
316 assessment. Moreover, the prospective population-based study design, large sample size, long
317 duration of follow-up, and detailed information on potential confounding variables, substantially
318 mitigate the possible complications from reverse causality and confounding bias. In several
319 sensitivity analyses, most of the documented associations remain materially unchanged,
320 indicating the robustness of our results.

321
322 Several potential limitations deserve attention. First, plasma omega-3 and omega-6 PUFAs were
323 measured only once at baseline. Their levels may vary with diet or other lifestyle factors, which
324 could cause misclassification over follow-up. However, some studies demonstrated that multiple
325 measurements of omega-3 PUFAs have been consistent for a 6-month period³⁹. Moreover, the
326 13-year within-person correlation for circulating omega-6 PUFAs was comparable to such
327 correlations for other major CVD risk factors⁴⁰. Thus, the single measurement of PUFAs at
328 baseline, although not perfect, provides us with adequate information to investigate the relative
329 long-term effects. Second, although we adjusted for many potential confounders in the model,
330 we cannot rule out the imprecisely measured and unmeasured factors. Third, we did not analyze
331 the individual omega-3 and omega-6 PUFAs due to their unavailability in the NMR-based
332 metabolomics data. Future studies should investigate the effects of specific individual PUFAs on
333 all-cause and cause-specific mortality. Last, although we included individuals of different

334 ancestries in the analysis, over 90% of the participants were of European ancestry. The
335 generalizability of our findings across ancestries requires future verification.

336

337 **Conclusions**

338 In this large prospective cohort study, we documented robust positive associations of the plasma
339 omega-6/omega-3 fatty acids ratio with the risk of all-cause, cancer, and CVD mortality.
340 Moreover, we found that plasma omega-3 and omega-6 PUFAs were independently and
341 inversely associated with the three mortality outcomes, with omega-3 fatty acids showing
342 stronger protective effects. Our findings support the active management of a high circulating
343 level of omega-3 fatty acids and a low omega-6/omega-3 ratio to prevent premature death.

344

345 **Declarations**

346 **Ethics approval and consent to participate**

347 The UK Biobank received ethical approval from the research ethics committee (reference ID: 11/
348 NW/0382). Written informed consent was obtained from participants.

349 **Consent for publication**

350 Not applicable.

351 **Availability of data and materials**

352 The datasets analyzed during the current study are available from the UK Biobank through an
353 application process (www.ukbiobank.ac.uk/).

354 **Competing interests**

355 The authors declare no competing interests.

356 **Funding**

357 Research reported in this publication was supported by the National Institute of General Medical
358 Sciences of the National Institute of Health under the award number R35GM143060 (KY). The
359 content is solely the responsibility of the authors and does not necessarily represent the official
360 views of the National Institutes of Health.

361 **Authors' contributions**

362 YZ performed data analysis, prepared visualizations, and wrote the original draft of the
363 manuscript. YS contributed to the data analysis. YS (yeshen@uga.edu) and KY
364 (kaixiong.ye@uga.edu) contributed equally to this project and should be considered co-
365 corresponding authors. They jointly designed and supervised the project. JTB contributed to the
366 interpretations of results. All authors critically edited the manuscript for important intellectual
367 content. The corresponding author (KY) attests that all listed authors meet the authorship criteria
368 and that no others meeting the criteria were omitted.

369 **Acknowledgements**

370 This research has been conducted using the UK Biobank Resource under Application Number
371 48818. We would like to express our heartfelt gratitude to the UK Biobank participants and
372 administrative staff.

373 **Abbreviations**

95% CI	95% confidence interval
ANOVA	Analysis of variance
BMI	Body mass index
CVD	Cardiovascular disease
DHA	Docosahexaenoic acid
EPA	Eicosapentaenoic acid
HR	Hazard ratio
Omega-3%	Omega-3 fatty acids to total fatty acids percentage
Omega-6%	Omega-6 fatty acids to total fatty acids percentage
PUFAs	Polyunsaturated fatty acids
Ref	Reference
SD	Standard deviation

374 **Supplementary Information**

375 **Additional file 1: Table S1.** Literature review.

376 **Additional file 2: Table S2.** Risk estimates of ratio of plasma omega-6 to omega-3 PUFAs with
377 all-cause, cancer and CVD mortality, stratified by potential risk factors, in the UK Biobank
378 Study. **Table S3.** Associations of plasma omega-3 PUFAs percentage with all-cause, cancer, and
379 CVD mortality risk in the UK Biobank Study. **Table S4.** Associations of plasma omega-6
380 PUFAs percentage with all-cause, cancer, and CVD mortality risk in the UK Biobank Study.
381 **Table S5.** Fully adjusted joint associations of plasma omega-3 PUFAs percentage and omega-6
382 PUFAs percentage with all-cause and cause-specific mortality in the UK Biobank Study. **Table**
383 **S6.** Associations of ratio of omega-6/omega-3 PUFAs with all-cause, cancer, and CVD mortality
384 risk in the UK Biobank, covariates including fish oil supplementation status. **Table S7.**
385 Associations of ratio of omega-6/omega-3 PUFAs with all-cause, cancer, and CVD mortality risk
386 in the UK Biobank Study, with multiple imputation for missing data. **Table S8.** Associations of
387 ratio of omega-6/omega-3 PUFAs with all-cause, cancer, and CVD mortality risk in the UK
388 Biobank Study, excluding those who died in the first follow-up year. **Table S9.** Baseline
389 characteristics of participants with missing exposure information and not included in the study.

390

391

392

393

394

395

396

397

398 **References**

- 399 1. Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204
400 countries and territories, 1990-2019: a systematic analysis for the Global Burden of
401 Disease Study 2019. *Lancet*. 2020;396(10258):1204-1222.
- 402 2. Harris WS, Von Schacky C. The Omega-3 Index: a new risk factor for death from
403 coronary heart disease? *Prev Med*. 2004;39(1):212-220.
- 404 3. Harris WS. The omega-3 index: from biomarker to risk marker to risk factor. *Curr*
405 *Atheroscler Rep*. 2009;11(6):411-417.
- 406 4. Harris WS, Luo J, Pottala JV, et al. Red blood cell polyunsaturated fatty acids and
407 mortality in the Women's Health Initiative Memory Study. *J Clin Lipidol*.
408 2017;11(1):250-259.e255.

- 409 5. Kleber ME, Delgado GE, Lorkowski S, März W, von Schacky C. Omega-3 fatty acids
410 and mortality in patients referred for coronary angiography. The Ludwigshafen Risk and
411 Cardiovascular Health Study. *Atherosclerosis*. 2016;252:175-181.
- 412 6. Harris WS, Tintle NL, Etherton MR, Vasan RS. Erythrocyte long-chain omega-3 fatty
413 acid levels are inversely associated with mortality and with incident cardiovascular
414 disease: The Framingham Heart Study. *J Clin Lipidol*. 2018;12(3):718-727.e716.
- 415 7. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl
416 for Hypertriglyceridemia. *N Engl J Med*. 2019;380(1):11-22.
- 417 8. Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn
418 oil on major adverse cardiovascular events in patients at high cardiovascular risk: the
419 STRENGTH randomized clinical trial. *JAMA*. 2020;324(22):2268-2280.
- 420 9. Delgado GE, März W, Lorkowski S, von Schacky C, Kleber ME. Omega-6 fatty acids:
421 opposing associations with risk-The Ludwigshafen Risk and Cardiovascular Health Study.
422 *J Clin Lipidol*. 2017;11(4):1082-1090.e1014.
- 423 10. Marklund M, Wu JHY, Imamura F, et al. Biomarkers of dietary omega-6 fatty acids and
424 incident cardiovascular disease and mortality. *Circulation*. 2019;139(21):2422-2436.
- 425 11. Wu JHY, Lemaitre RN, King IB, et al. Circulating omega-6 polyunsaturated fatty acids
426 and total and cause-specific mortality. *Circulation*. 2014;130(15):1245-1253.
- 427 12. Harris K, Oshima M, Sattar N, et al. Plasma fatty acids and the risk of vascular disease
428 and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE
429 study. *Diabetologia*. 2020;63(8):1637-1647.

- 430 13. Miura K, Hughes MCB, Ungerer JPJ, Green AC. Plasma eicosapentaenoic acid is
431 negatively associated with all-cause mortality among men and women in a population-
432 based prospective study. *Nutr Res.* 2016;36(11):1202-1209.
- 433 14. Otsuka R, Tange C, Nishita Y, et al. Fish and meat intake, serum eicosapentaenoic acid
434 and docosahexaenoic acid levels, and mortality in community-dwelling Japanese older
435 persons. *Int J Environ Res Public Health.* 2019;16(10).
- 436 15. Zhuang P, Wang W, Wang J, Zhang Y, Jiao J. Polyunsaturated fatty acids intake, omega-
437 6/omega-3 ratio and mortality: Findings from two independent nationwide cohorts. *Clin*
438 *Nutr.* 2019;38(2):848-855.
- 439 16. Shim JS, Oh K, Kim HC. Dietary assessment methods in epidemiologic studies.
440 *Epidemiol Health.* 2014;36:e2014009.
- 441 17. Simopoulos AP. Evolutionary aspects of diet and essential fatty acids. *World Rev Nutr*
442 *Diet.* 2001;88:18-27.
- 443 18. Simopoulos AP. The importance of the omega-6/omega-3 fatty acid ratio in
444 cardiovascular disease and other chronic diseases. *Exp Biol Med.* 2008;233(6):674-688.
- 445 19. Noori N, Dukkupati R, Kovesdy CP, et al. Dietary omega-3 fatty acid, ratio of omega-6 to
446 omega-3 intake, inflammation, and survival in long-term hemodialysis patients. *Am J of*
447 *Kidney Dis.* 2011;58(2):248-256.
- 448 20. Sudlow C, Gallacher J, Allen N, et al. UK Biobank: An Open Access Resource for
449 Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age.
450 *PLOS Medicine.* 2015;12(3):e1001779.

- 451 21. Julkunen H, Cichońska A, Slagboom PE, Würtz P, Nightingale Health UKBI. Metabolic
452 biomarker profiling for identification of susceptibility to severe pneumonia and COVID-
453 19 in the general population. *eLife*. 2021;10:e63033.
- 454 22. Würtz P, Kangas AJ, Soininen P, Lawlor DA, Davey Smith G, Ala-Korpela M.
455 Quantitative serum nuclear magnetic resonance metabolomics in large-scale
456 epidemiology: a primer on -Omic technologies. *Am J Epidemiol*. 2017;186(9):1084-1096.
- 457 23. Chua ME, Sio MCD, Sorongon MC, Dy JS. Relationship of Dietary Intake of Omega-3
458 and Omega-6 Fatty Acids with Risk of Prostate Cancer Development: A Meta-Analysis
459 of Prospective Studies and Review of Literature. *Prostate Cancer*. 2012;2012:826254.
- 460 24. Durrleman S, Simon R. Flexible regression models with cubic splines. *Stat Med*.
461 1989;8(5):551-561.
- 462 25. Li Z-H, Zhong W-F, Liu S, et al. Associations of habitual fish oil supplementation with
463 cardiovascular outcomes and all cause mortality: evidence from a large population based
464 cohort study. *BMJ*. 2020;368:m456.
- 465 26. Zhang Y, Zhuang P, He W, et al. Association of fish and long-chain omega-3 fatty acids
466 intakes with total and cause-specific mortality: prospective analysis of 421 309
467 individuals. *J Intern Med*. 2018;284(4):399-417.
- 468 27. van Buuren S, Groothuis-Oudshoorn K. mice: multivariate imputation by chained
469 equations in R. *J Stat Softw*. 2011;45(3):1 - 67.
- 470 28. Harris WS, Tintle NL, Imamura F, et al. Blood n-3 fatty acid levels and total and cause-
471 specific mortality from 17 prospective studies. *Nat Commun*. 2021;12(1):2329.
- 472 29. Lindberg M, Saltvedt I, Sletvold O, Bjerve KS. Long-chain n-3 fatty acids and mortality
473 in elderly patients. *Am J Clin Nutr*. 2008;88(3):722-729.

- 474 30. Chen GC, Yang J, Eggersdorfer M, Zhang W, Qin LQ. N-3 long-chain polyunsaturated
475 fatty acids and risk of all-cause mortality among general populations: a meta-analysis. *Sci*
476 *Rep.* 2016;6:28165.
- 477 31. Pertiwi K, Küpers LK, Goede Jd, Zock PL, Kromhout D, Geleijnse JM. Dietary and
478 circulating long-chain omega-3 polyunsaturated fatty acids and mortality risk after
479 myocardial infarction: a long-term follow-up of the Alpha Omega Cohort. *J Am Heart*
480 *Assoc.* 2021;10(23):e022617.
- 481 32. Lee S-H, Shin M-J, Kim J-S, et al. Blood eicosapentaenoic acid and docosahexaenoic
482 acid as predictors of all-cause mortality in patients with acute myocardial infarction-data
483 from Infarction Prognosis Study (IPS) Registry. *Circ J.* 2009;73(12):2250-2257.
- 484 33. Eide IA, Dahle DO, Svensson M, et al. Plasma levels of marine n-3 fatty acids and
485 cardiovascular risk markers in renal transplant recipients. *Eur J Clin Nutr.*
486 2016;70(7):824-830.
- 487 34. Pottala JV, Garg S, Cohen BE, Whooley MA, Harris WS. Blood eicosapentaenoic and
488 docosahexaenoic acids predict all-cause mortality in patients with stable coronary heart
489 disease: the Heart and Soul study. *Circ Cardiovasc Qual Outcomes.* 2010;3(4):406-412.
- 490 35. Miura K, Hughes MCB, Ungerer JPJ, Smith DD, Green AC. Absolute versus relative
491 measures of plasma fatty acids and health outcomes: example of phospholipid omega-3
492 and omega-6 fatty acids and all-cause mortality in women. *Eur J Nutr.* 2018;57(2):713-
493 722.
- 494 36. Warensjö E, Sundström J, Vessby B, Cederholm T, Risérus U. Markers of dietary fat
495 quality and fatty acid desaturation as predictors of total and cardiovascular mortality: a
496 population-based prospective study. *Am J Clin Nutr.* 2008;88(1):203-209.

- 497 37. de Lorgeril M, Renaud S, Salen P, et al. Mediterranean alpha-linolenic acid-rich diet in
498 secondary prevention of coronary heart disease. *Lancet*. 1994;343(8911):1454-1459.
- 499 38. Petrone AB, Weir N, Hanson NQ, et al. Omega-6 fatty acids and risk of heart failure in
500 the Physicians' Health Study. *Am J Clin Nutr*. 2012;97(1):66-71.
- 501 39. Kobayashi M, Sasaki S, Kawabata T, Hasegawa K, Akabane M, Tsugane S. Single
502 measurement of serum phospholipid fatty acid as a biomarker of specific fatty acid intake
503 in middle-aged Japanese men. *Eur J Clin Nutr*. 2001;55(8):643-650.
- 504 40. Clarke R, Shipley M, Lewington S, et al. Underestimation of risk associations due to
505 regression dilution in long-term follow-up of prospective studies. *Am J Epidemiol*.
506 1999;150(4):341-353.
- 507

Tables

Table 1. Selected participant characteristics at baseline across quintiles of the plasma omega-6/omega-3 PUFAs ratio (n=117,546).

Characteristics ^a	Omega-6/omega-3 ratio quintiles					P
	1 (median = 5.8) (n = 23,504)	2 (median = 7.5) (n = 23,504)	3 (median = 9.0) (n = 23,510)	4 (median = 10.8) (n = 23,516)	5 (median = 14.6) (n = 23,512)	
Age (years)	59.2 (7.2)	57.8 (7.7)	56.4 (8.0)	55.3 (8.2)	53.9 (8.2)	<0.001 ^b
Sex (male%)	39.5	43.6	46.5	48.2	51.4	<0.001 ^c
Ethnicity (n%)						
White	21,193 (90.6)	21,324 (91.1)	21,407 (91.5)	21,332 (91.2)	21,273 (90.9)	0.047 ^c
Black	144 (0.6)	124 (0.5)	127 (0.5)	130 (0.6)	146 (0.6)	
Asian	888 (3.8)	867 (3.7)	866 (3.7)	879 (3.8)	902 (3.9)	
Others	1,175 (5.0)	1,092 (4.7)	994 (4.2)	1,054 (4.5)	1,086 (4.6)	
Missing (n)	104	97	116	121	105	
BMI	27.3 (4.4)	27.6 (4.6)	27.6 (4.8)	27.5 (4.9)	27.2 (5.1)	<0.001 ^b
Missing (n)	77	90	84	78	102	
Smoking status (n%)						<0.001 ^c
Never	12,890 (55.1)	12,672 (54.2)	12,875 (55.0)	12,788 (54.7)	12,605 (53.9)	
Previous	8,971 (38.4)	8,686 (37.1)	8,201 (35.0)	7,813 (33.4)	7,018 (30.0)	
Current	1,519 (6.5)	2,025 (8.7)	2,324 (9.9)	2,786 (11.9)	3,768 (16.1)	
Missing (n)	124	121	110	129	121	
Alcohol status (n%)						<0.001 ^c
Never	895 (3.8)	892 (3.8)	953 (4.1)	1059(4.5)	1343 (5.7)	
Previous	736 (3.1)	752 (3.2)	778 (3.3)	841 (3.6)	1161 (5.0)	
Current	21,815 (93.0)	21,817 (93.0)	21,720 (92.6)	21,552 (91.9)	20,943 (89.3)	
Missing (n)	58	43	59	64	65	
Physical activity (n%)						<0.001 ^c
High	7,634 (40.1)	7,492 (39.3)	7,518 (39.5)	7,669 (40.5)	7,984 (42.2)	
Moderate	7,988 (41.9)	7,909 (41.5)	7,800 (41.0)	7,624 (40.3)	7,287 (38.5)	
Low	3,430 (18.0)	3,645 (19.1)	3,715 (19.5)	3,643 (19.2)	3,640 (19.2)	
Missing (n)	4,452	4,458	4,447	4,580	4,601	
Fish oil supplementation (Yes%)	48.6	38.1	30.4	23.8	15.9	<0.001 ^c

Missing (n)	73	64	97	106	97	
Omega-3 percentage	6.7 (1.4)	5.0 (0.5)	4.2 (0.4)	3.6 (0.4)	2.6 (0.5)	<0.001 ^b
Omega-6 percentage	36.1 (3.7)	37.3 (3.5)	38.1 (3.3)	38.9 (3.2)	40.1 (3.1)	<0.001 ^b

^a All variables measured at baseline are presented as mean (SD) unless otherwise specified.

^b From the ANOVA test for continuous variables.

^c From the Pearson's Chi-squared test for categorical variables.

Table 2. Associations^a of the plasma omega-6/omega-3 PUFAs ratio with all-cause, cancer, and CVD mortality risk in the UK Biobank

Omega ratio variable forms	Causes of death								
	All-cause			Cancer			Cardiovascular diseases		
	Number of deaths	Partially adjusted associations ^b	Fully adjusted associations ^c	Number of deaths	Partially adjusted associations ^b	Fully adjusted associations ^c	Number of deaths	Partially adjusted associations ^b	Fully adjusted associations ^c
		HR (95% CI)	HR (95% CI)		HR (95% CI)	HR (95% CI)		HR (95% CI)	HR (95% CI)
Continuous	4,733	1.02 (1.02-1.03)	1.02 (1.02-1.03)	2,585	1.02 (1.01-1.03)	1.01 (1.00-1.02)	1,017	1.02 (1.01-1.03)	1.02 (1.01-1.03)
Quintiles (median)									
1 (5.8)	900	1.00 (ref)	1.00 (ref)	512	1.00 (ref)	1.00 (ref)	202	1.00 (ref)	1.00 (ref)
2 (7.5)	896	1.07 (0.97-1.17)	1.02 (0.91-1.13)	539	1.15 (1.02-1.30)	1.11 (0.97-1.27)	176	0.92 (0.75-1.13)	0.87 (0.69-1.11)
3 (9.0)	868	1.09 (0.99-1.19)	1.03 (0.92-1.14)	469	1.06 (0.94-1.21)	1.01 (0.87-1.16)	187	0.99 (0.81-1.21)	0.91 (0.72-1.16)
4 (10.8)	980	1.31 (1.20-1.44)	1.26 (1.14-1.40)	529	1.30 (1.15-1.47)	1.26 (1.10-1.45)	208	1.17 (0.96-1.42)	1.17 (0.93-1.47)
5 (14.6)	1,089	1.55 (1.42-1.70)	1.42 (1.28-1.57)	533	1.42 (1.25-1.60)	1.31 (1.13-1.50)	244	1.42 (1.17-1.72)	1.40 (1.12-1.75)
<i>P</i> _{trend}		<0.001	<0.001		<0.001	<0.001		<0.001	<0.001

Abbreviations: CI, confidence interval; HR, hazards ratio; ref, reference.

^a From Cox proportional hazards regression.

^b Adjusted for age (years; continuous), sex (male, female), race (White, Black, Asian, Others), Townsend deprivation index (continuous), assessment Centre.


^c Adjusted for age (years; continuous), sex (male, female), race (White, Black, Asian, Others), Townsend deprivation index (continuous), assessment Centre, BMI (kg/m²; continuous), smoking status (never, previous, current), alcohol intake status (never, previous, current), physical activity (low, moderate, high).


Figure Legends

Figure 1. Risk estimates of all-cause mortality for the highest compared with the lowest quintile of the ratio of plasma omega-6 to omega-3 PUFAs, stratified by potential risk factors. Results were adjusted for age (years; continuous), sex (male, female), race (White, Black, Asian, Others), Townsend deprivation index (continuous), assessment Centre, BMI (kg/m²; continuous), smoking status (never, previous, current), alcohol intake status (never, previous, current), physical activity (low, moderate, high).


Figure 2. Risk estimates of cause-specific mortality for the highest compared with the lowest quintile of the ratio of plasma omega-6 to omega-3 PUFAs, stratified by potential risk factors. Results were adjusted for age (years; continuous), sex (male, female), race (White, Black, Asian, Others), Townsend deprivation index (continuous), assessment Centre, BMI (kg/m²; continuous), smoking status (never, previous, current), alcohol intake status (never, previous, current), physical activity (low, moderate, high).

Figure 3. Associations of the ratio of omega-6/omega-3 PUFAs with all-cause and cause-specific mortality evaluated using restricted cubic splines. Hazard ratios and omega ratios are presented in the vertical and horizontal axis, respectively. The best estimates and their confidence intervals are presented as solid red lines and dotted black lines, respectively. The ratio 4 was selected as a reference level, and the x-axis depicts the ratio from 0 to 40. Potential nonlinearity was identified for all-cause mortality ($p = 0.011$) and CVD-caused mortality ($p = 0.011$), but not for cancer-caused mortality ($p > 0.05$). All HRs are adjusted for age (years; continuous), sex (male, female), race (White, Black, Asian, Others), Townsend deprivation index (continuous), assessment Centre, BMI (kg/m²; continuous), smoking status (never, previous, current), alcohol intake status (never, previous, current), physical activity (low, moderate, high).






All-cause Mortality



Cancer Mortality



CVD Mortality

